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ABSTRACT: A 1,7-bis(alkylamino)diazachrysene-based small
molecule was previously identiﬁed as an inhibitor of the
botulinum neurotoxin serotype A light chain metalloprotease.
Subsequently, a variety of derivatives of this chemotype were
synthesized to develop structure-activity relationships, and all
are inhibitors of the BoNT/A LC. Three-dimensional analyses
indicated that half of the originally discovered 1,7-DAAC
structure superimposed well with 4-amino-7-chloroquinoline-
based antimalarial agents. This observation led to the discovery that several of the 1,7-DAACderivatives are potent in vitro inhibitors
of Plasmodium falciparum and, in general, are more eﬃcacious against CQ-resistant strains than against CQ-susceptible strains. In
addition, by inhibiting β-hematin formation, the most eﬃcacious 1,7-DAAC-based antimalarials employ a mechanism of action
analogous to that of 4,7-ACQ-based antimalarials and are well tolerated by normal cells. One candidate was also eﬀective when
administered orally in a rodent-based malaria model. Finally, the 1,7-DAAC-based derivatives were examined for Ebola ﬁlovirus
inhibition in an assay employing Vero76 cells, and three provided promising antiviral activities and acceptably low toxicities.
’ INTRODUCTION
The present manuscript describes a series of 1,7-bis(ami-
noalkyl)diazachrysene (1,7-DAAC)-based derivatives that inhi-
bit three diﬀerent pathogenic targets: the botulinum neurotoxin
serotype A light chain (BoNT/A LC) (a Zn(II) metalloprotease
that is responsible for the paralysis associated with botulism),
Plasmodium falciparum (which causes malaria), and the Ebola
ﬁlovirus (which causes hemorrhagic fever). The three targets are
described below.
Botulinum neurotoxins (BoNTs), secreted by anaerobic,
spore-forming bacterium Clostridium botulinum, are the most
potent of bacterial toxins.1 Due to their ease of dissemination2
and lethality,3 BoNTs are classiﬁed as category A, highest priority
biothreat agents by the Centers for Disease Control and Preven-
tion (CDC).4
There are seven known BoNT serotypes (designated A-G).3
All are composed of a heavy chain (HC) component and a light
chain (LC) component.5 The LC is a Zn(II) metalloprotease.
The HC mediates translocation into the neuronal cytosol. After
cell internalization, the LC is liberated from the HC, and
depending on the serotype, cleaves one of three proteins
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composing the soluble N-ethylmaleimide-sensitive fusion pro-
tein attachment protein receptor (SNARE) complex.3 The
proteolysis of SNARE proteins prevents the release of acetylcho-
line ﬁlled vesicles into neuromuscular junctions, resulting in the
ﬂaccid paralysis associated with botulism.3,5
Currently, the only treatment for BoNT poisoning is the
administration of antitoxin vaccine.3,6 However, the vaccine
cannot inhibit the toxin once it penetrates into the neuronal
cytosol, and the only subsequent life-saving option available is
clinically expensive, longer-termmechanical ventilation.2b,6 Con-
sequently, due to the currently limited options for treating BoNT
poisoning, there is a signiﬁcant interest in the development of a
drug(s) that will rescue neurons postintoxication, with the vast
majority of research to date focusing on the BoNT/A LC.3,7 This
serotype LC cleaves SNARE component synaptosomal asso-
ciated protein of 25 kDa (SNAP-25)8 and is the longest acting of
the LC serotypes in the neuronal cytosol.9
Malaria is a devastating disease resulting from mosquito-
vectored infection by protozoan parasites of the genus Plasmo-
dium, with P. falciparum being the predominant species in sub-
Saharan Africa.10 It is estimated that 300-500 million people
contract malaria annually, with over 1 million deaths occurring
mostly in young children and pregnant women.11 Aggravating
the problems associated with this illness has been/is the devel-
opment of widespread drug-resistance to chloroquine (CQ),
which was the standard antimalarial drug formany years,10 as well
as the very recently reported, reduced clinical eﬃcacy of drug
combinations containing artemisinin, mostly in SE Asia.12
During the complex lifecycle of P. falciparum,10 there is a
debilitating, cyclical blood stage during which the protozoan
infests red blood cells (RBC), digests hemoglobin (Hb) within
its food vacuole (FV) (via proteolysis), replicates, and ruptures
the RBC. This event leads to the release of new merozoites that
continue the intraerythrocytic infestation cycle.
The biodegradation products of FV mediated Hb consump-
tion primarily include: (1) insoluble hemozoin crystals (resulting
from Hb heme detoxiﬁcation) and (2) individual amino acids
(resulting from Hb globin digestion). Commonly used anti-
malarial drugs are thought to kill the parasite either by producing
toxic free radicals (for the latest results in the ﬁeld, see refs 10,13)
or by blocking the formation of β-hematin. This latter mecha-
nism appears to be employed by 4-amino-7-chloroquinoline (4,7-
ACQ)-based antimalarial drugs, and results in the inhibition of
heme detoxiﬁcation, i.e., the consequent increase in the concen-
tration of toxic heme within the FV causes parasite death.10,14
However, it should be noted that the heme detoxiﬁcation path-
way is not directly involved in CQ resistance. Instead, resistance
is conferred by drug transporter (PfCRT, Pgh1, and PfMRP)
mutations that alter drug accumulation in the parasite by either
reducing drug uptake, or increasing drug eﬄux, or both.15 In
addition, it is important to note that a very recent study indicates
that reduced CQ accumulation is not the underlying cause of CQ
resistance.16 Hence, there is no direct correlation between in
vitro antimalarial activity and heme binding and/or inhibition of
hemozoin formation. Therefore, other parameters such as lipo-
philicity and pH-driven drug accumulation in the parasite’s FV
must play an important role in antimalarial activity.14b Given
these discoveries, signiﬁcant focus has been placed on the
synthesis and development of novel 4,7-ACQ-based molecules
that inhibit hemozoin formation17 and on the screening of
compound libraries to detect novel chemotypes with similar
antimalarial mechanisms.18 Compounds that are currently of
signiﬁcant interest include hematin binding 4,7-ACQ-hybrid
drug reversals,19 acridones,20 4,7-ACQ-astemizole-21 and 4,7-
ACQ-chlotrimazol-derived hybrids,22 and new 4,7-ACQ and
acridine derivatives.23
The Ebola ﬁlovirus (EBOV) is a member of the Family
Filoviridae (Order Mononegavirales).24 Genetically, EBOV is a
nonsegmented, single-stranded negative sense RNA virus that is
endemic to sub-Saharan Africa, and sporadic outbreaks of
naturally occurring EBOV Zaire (Zaire virus) have been reported
to cause severe hemorrhagic fever with a lethality rate approach-
ing 90%.25
Major concerns regarding this virus include its potential global
spread (due to increasing international travel) and its possible
use as a biological weapon.4 Therefore, like BoNTs, this patho-
gen is listed as a CDC Category A biothreat agent,4 as there are
no approved therapeutic options available for the prophylaxis
and/or treatment of infected individuals. Currently, the only
medical response to an “outbreak” relies on systematic case
identiﬁcation and contact tracing strategies, and the immediate
isolation of suspect cases in specialized isolation wards.24,26
Therefore, a vaccine(s), as well as new antiﬁlovirus drugs, are
needed to counter this pathogen; however, a review of the
literature aﬀorded only a handful of small molecules that act as
EBOV inhibitors.27
Herein, we provide results indicating that derivatives of a
single chemotype (i.e., 1,7-DAAC-based small molecules) pos-
sess the ability to inhibit the three unrelated pathogens
(described above): a bacterial toxin (the BoNT/A LC), a proto-
zoan (malaria), and a ﬁlovirus (EBOV).
With respect to the importance of discovering small molecules
that employ diﬀerent mechanisms of action to treat more than
one target/pathogen, this paradigm is a cost-eﬀective means for
treating diseases in general and especially those aﬀecting (or that
would aﬀect) small populations as well as populations in third
world countries (e.g., malaria).28 One example of such a small
molecule is miltefosine, which was originally developed to treat
breast cancer but was later found to be an eﬀective treatment for
visceral leishmaniasis (a sand-ﬂy transmitted parasite disease
estimated to kill 500000 people a year).29 A second example is
Adefovir dipivoxil. This drug is used to treat chronic hepatitis B
virus infection but was subsequently identiﬁed as a competitive
inhibitor of anthrax edema factor (a key virulence factor in
anthrax pathogenesis).30
’RESULTS AND DISCUSSION
To initially discover novel small molecule (nonpeptidic)
inhibitors (SMNPIs) of the BoNT/A LC, high-throughput
screens of small molecule libraries were conducted and “hits”
from the screens were veriﬁed using a previously reported
HPLC-based assay.31 The chemical diversity of the initially
discovered SMNPIs ranged from the rigid natural product
Michellamine B to ﬂexible bis-(4,7-ACQ) antimalarial agents.31
Following the three-dimensional (3-D) superimpositions of
shared SMNPI chemical and steric features led to the generation
of a common pharmacophore for BoNT/A LC inhibition.31 In
subsequent studies, the pharmacophore provided the basis for
developing 3-D search queries that were used to database mine
more potent SMNPIs.32 Interestingly, two new SMNPI chemo-
types that were discovered included 4,7-ACQ-cholic acid
hybrids33 and 4,7-ACQ-adamantane hybrids.34 Additionally, a
1,7-DAAC-based SMNPI, 1 (Scheme 1), was also database
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mined from the NCI Open Repository.35 Following 1 was used
to unite diﬀerent SMNPI chemotypes in a reﬁned 3-Zone
pharmacophore.35 Of signiﬁcance to the research reported here-
in, 3-D superimpositions of the SMNPIs used to develop the
reﬁned 3-zone pharmacophore model indicated that 1 and
previously identiﬁed SMNPI 235 (which is also an antimalarial
agent31) partially superimposed with remarkably good chemical
and steric complementarity (Figure 1A). Not surprisingly, when
1 was superimposed with antimalarial drug CQ, which was also
previously found to weakly inhibit the BoNT/A LC,31,35 the
same complementary chemical and steric convergence was
observed. This structural convergence is even more pronounced
when 1 and two condensed CQ molecules are superimposed
(Figure 1B). This observation led to the hypothesis that 1 and its
derivatives might possess antimalarial activity, and initial in vitro
screening against P. falciparum revealed that these compounds
are active against the parasite. Additional toxicity and pharma-
cokinetics proﬁling, followed by the in vivo testing of one of the
most potent of the derivatives, also demonstrated signiﬁcant
potential for developing 1,7-DAAC-based SMNPIs as antimalar-
ial therapeutics (vide infra).
Finally, it was previously discovered that 9 (Scheme 1)
possesses anti-EBOV eﬃcacy in vivo with no toxicity.27a Conse-
quently, all of our 1,7-DAAC derivatives were examined for anti-
EBOV activities in a cell-based assay, and it was discovered that
three of the derivatives aﬀord good cellular protection, with very
low toxicities, when dosed at 20 μM concentrations. Hence, our
results indicate that 1,7-DAAC-based derivatives represent new
leads for therapeutic development against three diﬀerent patho-
genic targets.
The Synthesis of DAAC-Based Derivatives. Prior to the
discovery that 1,7-DAAC-based SMNPI 1 was also active against
P. falciparum strains as well as the EBOV filovirus, derivatives
were synthesized to provide SAR for the development of this
chemotype as a potential therapeutic to counter BoNT/A
poisoning. Specifically, 1,7-DAAC derivatives exploring the bis-
(alkylamino) side-chains of 1 were generated (Scheme 1). In
Scheme 1, a brief synopsis of the synthetic method used to obtain
the derivatives is displayed (see the Experimental Section for
details). First, commercially available 1,5-diaminonaphthalene
was used to prepare intermediate 4 via the Conrad-Limpah
reaction. Following, 4 was reacted with POCl3 to give dichloride
5 in 82% yield. Nucleophilic substitution with a variety of
diamines, followed by HCl salt formation, provided 1 and
derivatives 6-17 (overall yields ranged from 45% to 72%).
Inhibition of the BoNT/A LC. Table 1 displays the inhibitory
efficacies of 1 and 6-17 when examined in vitro at 20 μM
concentrations employing a well established HPLC-based assay
for BoNT/A LC inhibition.36 Note, as indicated above, the 1,7-
DAAC derivatives were generated to determine the effects of
Figure 1. Compound 1 and antimalarial agents (that are also SMNPIs
of the BoNT/A LC) superimpose well. (A) half of the structure of 1
superimposes with good chemical and steric complementarity with half
of previously identiﬁed antimalarial agent/BoNT/A LC inhibitor 2.
Carbon atoms are green for 1 and orange for 2. Nitrogen atoms are blue
and chlorine atoms are yellow. (B) Two CQ (chloroquine) molecules
superimposed with 1.CQ carbons aremagenta. All other atom colors are
as indicated for (A).
Scheme 1a
a (a) Ethyl acetoacetate, TsOH/EtOH, Δ; (b) MeSO3H/P2O5, 90 C; (c) POCl3, 90 C; (d) RNH2, Ar, Δ; (e) HCl/EtOH, rt.
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modifying the bis(alkylamino) side-chains (i.e., the symmetrical
moieties extending from diazachrysene core (Scheme 1)) on
BoNT/A LC inhibitory efficacy. Overall, the SAR indicates that
propylamino linkers, as well as a butylamino linker, provide
slightly increased inhibitory efficacies versus corresponding
derivatives possessing ethyl linkers (Table 1). Specifically, 6
and 7, 9, 1, 12, 14, and 16 are all consistently more potent than
corresponding derivatives 8, 10, 11, 13, 15, and 17, respectively
(Table 1).
By contrast, diﬀerent substitutions on the side chain terminal
nitrogens did not demonstrate the same consistency with respect
to BoNT/A LC inhibition. For example, primary amine deriva-
tives 6 and 7 are slightly more potent than 9 and 1, which possess
N,N-dimethyl and N,N-diethyl substituents, respectively, and 14
and 17, which incorporate the side chain nitrogens in piperidine
and morpholine rings, respectively. However, 12, which incor-
porates the side chain nitrogens in pyrrolidine rings is equipotent
to 6, and more potent than 7 and 14, as well as all other deri-
vatives presented in Table 1. These results are indicative of
potential steric limitations for side chain amino substitutions
within the conﬁnes of their binding sites. Finally, it is notable that
the inhibition data indicates that incorporating terminal morpho-
line rings (16 and 17 in Table 1) has amore pronounced negative
impact on inhibitory eﬃcacy versus all other presented deriva-
tives. This data appears to indicate that either an unfavorable
hydrophobic-polar or polar-polar contact between one (or
both) of the morpholine ring oxygens and an enzyme residue(s)
is occurring in the BoNT/A LC binding site. In agreement with
this hypothesis, inhibition data shows that 14, which possesses
hydrophobic carbon atoms in the same positions as the oxygen
atoms of the morpholine rings of 16, is a more potent SMNPI.
To determine the type of inhibition kinetics employed by 1,7-
DAAC-derived SMNPIs, Ki values were determined for deriva-
tive pair 7 and 8. The inhibition kinetics for 7 and 8 mirror their
% inhibition data (Table 1), with the Ki values for these SMNPIs
= 8.1 μM ((1.2 μM) and 8.7 μM ((0.9 μM), respectively.
These data indicate that 7 and 8 are among the most potent of
non-Zn(II) chelating SMNPIs reported in the literature to date.
Additionally, plots of BoNT/A LC inhibition, versus increasing
concentrations of 7 and 8, indicate that these SMNPIs are
competitive inhibitors (see Supporting Information, Figure S1).
Consequently, on the basis of the fact that only conservative
modiﬁcations were made to the bis-alkylamino side-chains of 1
and 6-17, it follows that SMNPIs 1, 6, and 9-17 should also be
competitive inhibitors.
Furthermore, on the basis of the SAR for 1 and 6-17 and the
relatively close inhibitory ranges for the majority of the derivatives,
additional syntheses are required to further explore the impact of
more pronounced alkylamino side chain substitutions.37
Antimalarial Activity: The Inhibition of P. falciparum
Strains. As shown in Figure 1, classical 4,7-ACQ-based anti-
malarial agents 2 and CQ superimpose well with 1 (Figure 1).
These observations led to the hypothesis that 1,7-DAAC-based
SMNPIs of the BoNT/A LC (Table 1) might inhibit P. falcipar-
um by employing the same, or a similar, mechanism of action as
that postulated for 4,7-ACQ-based antimalarial agents (i.e., the
inhibition of hemozoin formation).
Subsequently, 1 and 6-17 were screened in vitro38 against
three P. falciparum strains: D6 (a clone from the Sierra I/UNC
isolates that is susceptible to CQ (CQS) and pyrimethamine, but
which has reduced susceptibility to meﬂoquine and halo-
fantrine), W2 (a clone of the Indochina I isolate that is resistant
to chloroquine (CQR) and pyrimethamine, but which is suscep-
tible to meﬂoquine), and C235 (a multidrug-resistant strain
derived from Thailand, MDR) (Table 1).
In general, our hypothesis was correct, as the majority of the
1,7-DAAC SMNPIs are very potent antimalarial agents, inhibit-
ing the proliferation of all CQR, MDR, and CQS P. falciparum
strains with low nanomolar range eﬃcacies. SMNPIs 7 and 8,
which possess side chains containing a primary amino group,
are the least active of the derivatives (Table 1). By contrast,
the inhibitory eﬃcacies of the 1,7-DAAC derivatives gradually
Table 1. BoNT/A LC Inhibition and Antimalarial Activities for 1,7-DAAC Derivatives 1 and 6- 17
antimalarial activity IC50 (IC90), nM
compd BoNT/A LC % inhibition (μM)a D6 b W2 c C235 d RI e
6 72.32 ((4.6)
7 70.0 ((1.5) 708.29 (1011.31) 1701.59 (3262.40) 2030.86 (3049.06) 2.40/2.87
8 62.7 ((2.0) 270.29 (355.08) 871.25 (1785.20) 1021.04 (1761.50) 3.22/3.78
9 68.9 ((0.3) 103.47 (210.18) 352.71 (708.66) 54.82 (698.68) 3.41/0.53
10 57.0 ((2.2) 15.61 (20.82) 9.19 (31.23) 15.27 (26.02) 0.59/0.98
1 64.7 ((1.8) 30.01 (49.53) 8.65 (46.73) 66.50 (285.70) 0.29/2.22
11 55.4 ((0.6) 6.01 (9.01) 3.48 (10.12) 3.32 (3.79) 0.57/0.55
12 73.5 ((0.2) 14.84 (39.41) 7.75 (25.37) 34.29 (95.17) 0.52/2.31
13 60.3 ((1.8) 16.76 (32.28) 8.11 (28.00) 25.90 (40.28) 0.48/1.54
14 66.1 ((2.9) 9.26 (17.43) 6.98 (22.50) 24.84 (41.22) 0.75/2.68
15 63.4 ((3.9) 8.79 (13.21) 5.50 (15.37) 10.55 (14.93) 0.62/1.20
16 55.6 ((0.1) 5.23 (8.47) 2.00 (6.38) 8.05 (17.36) 0.38/1.54
17 39.0 ((2.0) 5.93 (12.60) 6.12 (11.50) 9.84 (16.48) 1.03/1.66
CQ f 12.27 (16.11) 456.20 (697.97) 138.82 (373.25) 38.18/11.31
MFQ f 15.70 (39.09) 4.93 (15.25) 36.50 (134.07) 0.31/2.32
ART g 9.00 (12.80) 6.70 (11.50) 13.04 (17.40) 0.74/1.45
a% inhibition calculated at 20 μM conc. b P. falciparum African D6 clone. c P. falciparum Indochina W2 clone. d P. falciparum multidrug resistant C235
strain (Thailand). eThe resistance index (RI) is deﬁned as the ratio of the IC50 for the resistant versus sensitive strain, W2/D6 and C235/D6,
respectively. fControl drug (the average of seven replicates). gThe average of greater than eight replicates.
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improve with increasing substitution on the basic side chain
nitrogens (compare 7 and 8 versus 1, and 9-11 (Table 1)).
Moreover, the introduction of piperidine moieties (14, 15)
further increases antimalarial activity, while the introduction of
a heteroatom in the piperidine rings (to provide the morpholine
substituents of 16 and 17) further enhanced activity against all
examined P. falciparum strains (Table 1). Overall, out of 12
examined 1,7-DAAC derivatives, nine possess pronounced anti-
malarial activities (1, and 10-11), with the most potent anti-
malarial agents possessing diethyl (11), piperidine (14, 15), and
morpholine substituents (16, 17) (Table 1). It is important to
note that these low IC50 values are unusual for nonperoxide
derived antimalarials: (1) nine derivatives with activities below
10 nM against CQR W2 strain and (2) 1 and 10-17 are generally
more potent against P. falciparumCQRW2 strain than against CQS
D6 strain (RI = 0.29-0.75; RIART = 0.74) (Table 1). It should
also be emphasized that 11, 16, and 17 are more potent than
standard antimalarial drugs CQ, MFQ, and ART (Table 1). In
particular, the ratios of increased inhibitory potencies indicate
that these SMNPIs are: 1.5-2 times more potent against D6
than CQ, MFQ, and ART, respectively, 1.5-300 times more
potent against W2 than MFQ, ART, and CQ, respectively, and
4-42 times more potent against C235 than ART, MFQ, and
CQ, respectively (Table 1).
To obtain basic information about the antimalarial mechanism
of action employed by the 1,7-DAAC-based SMNPIs shown in
Table 1, derivatives 13, 16, and 17were screened for suppression
of β-hematin formation using a previously described β-hematin
inhibitory activity assay (BHIA).39 Speciﬁcally, the assay moni-
tors small molecule-based interference of the heme detoxiﬁcation
process employed by P. falciparum. In line with our hypothesis
that 1,7-DAAC-based SMNPIs, like 4,7-ACQ-based antimalar-
ials, would interfere with the heme detoxiﬁcation mechanism, the
results in Table 2 indicate that 13, 16, and 17 display dose-
dependent inhibition of β-hematin formation, with IC50 values
that are considerably lower than that of CQ, thus demonstrating a
signiﬁcantly better ability to interact with hematin than CQ (as
well as conﬁrming our hypothesis). For information on dose-
dependent inhibition of β-hematin formation by the select
SMNPIs, see Supporting Information, Figure S2.
Analysis of 1,7-DAAC Toxicity. Because the investigated
SMNPIs are based on the 1,7-DAAC scaffold, close attention
was paid to the possibility of toxicity issues.40 First, bis(N,N-
diethyl)substituted derivative 11 and bismorpholino substituted
derivatives 16 and 17 were chosen for advanced toxicity screen-
ing due to their potencies against the CQR W2 strain and the
MDR C235 strain (RI11 = 0.57/0.55, RI16 = 0.38/1.54, RI17 =
1.03/1.66, respectively (Table 1)). In brief, SMNPI cytotoxicities
were examined in a rat macrophage cell line, and low toxicities
were observed for all three derivatives (IC50 value range =
∼7000-10000 nM, Table 3). Moreover, the potencies of these
SMNPIs were further supported by corresponding IC90 values
(Table 3), which are substantially higher than those of standard
antimalarial drugs CQ, MFQ, and ART.41,42 Another important
characteristic of 11, 16, and 17 is their lack of toxicity with respect
to their high antimalarial activities against all three P. falciparum
strains. In particular, all possess very high selectivity indices (SIg
1000 (Table 3)).
No evidence of in vivo clinical toxicity was noted in P. berghei
(P-line) malaria-infected mice (outbred ICR mice, Mus
musculus) administered 11 at a dose of 160 mg/kg of body
weight for 3 consecutive days by oral route, as evidenced by a lack
of overt physical or behavioral changes in treated mice. More-
over, no signs of toxicity were observed as noted by twice daily
observations of individual mouse behavior and appearance and
by routine gross necropsy lesions indicating death due to
fulminant malaria infection.
In addition, it is notable that 16 and 17 were examined against
the National Cancer Institute’s panel of 60 human tumor cell
lines starting at concentrations of 10-4 M,40 and their inhibitory
activities were found to be very low, with mean growth percents
of 92% and 91%, respectively; hence, these data indicate that 16
and 17 are not toxic to a range of cancer cells.
In vitro metabolism studies were also performed with 11, 16,
and 17 to assess their bioavailabilities upon oral administration.
Metabolic stability assays were performed using mouse and
human liver microsomes (MLM and HLM), respectively.43
Following, our results indicated that 11 and 17 were metaboli-
cally stable, with a half-lives (t1/2) >60 min in MLM and HLM,
while bismorpholino derivative 16was metabolically stable when
exposed to MLM (t1/2 > 60 min) and appreciably stable when
exposed to HLM: t1/2 = 40 min (Table 3).
44
We presume that the low toxicities observed for the 1,7-
DAAC-based derivatives result from their N-substitutions at
positions C(1) and C(7), as the side chains may suppress the
metabolic activation and ultimate formation of DNA adducts.40
In this regard, toxicity issues need to be investigated in more
detail; nevertheless, our initial results are encouraging, and
prompted the in vivo testing of 11.
In Vivo Analysis of 11. On the basis of the favorable toxicity
profiles indicated above, 11 was examined for antimalarial
efficacy in a mouse model (groups of five mice were employed).
A modified Thompson test model of malaria was used to
determine the blood schizonticidal efficacy of 11. In this model,
ICR mice are infected with P. berghei-infected red blood cells on
day 0. SMNPI 11 was administered orally (80 mg/kg) on days 3,
4, and 5 after parasite inoculation (i.e., postestablishment of
blood stage infection); the establishment of blood stage infection
was confirmed by positive blood smear results for all mice on
study day 3 (prior to SMNPI administration). SMNPI 11 cured
one mouse out of five tested, as evidenced by a negative blood
smear obtained on day 31 postinfection. In the other four mice in
the test group, 11 provided blood stage suppressive activity, with
the mice succumbing to infection between days 13 and 21
(postparasite inoculation). In contrast, control mice showed a
high degree of parasitemia, succumbing to infection on days 7-8
(postparasite inoculation).
The presumptive causal prophylactic activity50 of 11 was also
investigated in an ICR mouse P. berghei (ANKA strain) sporo-
zoite challenge model. Speciﬁcally, mice were inoculated with
sporozoites on day 0, and 11was administered on days-1, 0, and
Table 2. β-Hematin Inhibitory Assay for 1,7-DAAC Deriva-
tives 13, 16, and 17a
compd BHIA
13 0.401( 0.09
16 0.520( 0.12
17 0.473( 0.04
CQ 1.09( 0.10
a IC50 values represent the molar equivalents of compound, relative to
hemin, that inhibit β-hematin formation by 50%. Data are the mean (
SD of four replicates from two diﬀerent experiments performed in
duplicate.
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þ1 (to investigate its prophylactic potential). On day 0, SMNPI
11 was dosed one hour prior to sporozoite inoculation. Results
from these studies indicate that 11 does not provide prophylactic
protection; however, 11 did delay parasite patency by 1 to 2 days,
relative to control mice (all controls showed parasitemia on
day 4), in three out of ﬁve mice that were orally dosed with
160 mg/kg for 3 days. Moreover, a lower prophylactic dose of 11
(40 mg/kg) resulted in a delayed patency of 1 day in one out of
ﬁve mice. In both the Thompson blood stage and causal
prophylaxis in vivo models, 11 was well tolerated and did not
produce overt clinical manifestations of toxicity, as noted by
twice daily observations of individual mouse behavior and
appearance.
Routine necropsy was conducted on all mice treated with 11,
and the results clearly showed that mice evaluated in both the
Thompson blood stage and causal prophylaxis in in vivo models
died as a result of parasitemia (and not from 11 related toxicity),
as evidenced by pale and emaciated carcasses, the presence of
dark-gray swollen gross lesions on the liver, and splenomegaly, all
of which are indicative of malaria-induced death. The same signs
of parasitemia-induced death were also observed during the
necroscopy of control mice. Importantly, no toxicity was observed
for mice treated with 11, as indicated by twice daily observations of
individual mouse behavior and appearance and by routine gross
necropsy lesions that are indicative of mouse death resulting
from fulminant malaria infection.
The Analysis of 1,7-DAAC-Based Derivatives for Anti-
EBOV Activity. As indicated in the Introduction, it was pre-
viously discovered that 9 counters EBOV infection in vivo.27a
Moreover, in the same publication,27a it was found that 9
is a broad-spectrum SMNPI that inhibits not only EBOV
(a filovirus) but also other genetically distinct positive and
negative-strand RNA viruses including: Rift Valley fever
(a Bunyavirus), Dengue virus (a Flavivirus), hepatitis C virus
(a Flavivirus), and HIV-1 (a retrovirus). Thus, it is hypothesized
that the antiviral activity of 9, and other1,7-DAAC-based
SMNPIs, results from the modulation of common cellular path-
ways involved in viral assembly and budding (which are utilized
by a wide array of evolutionarily distant virus families).51 Recent
findings27a prompted the examination of 1 and 6-17 for
potential anti-EBOV activity. The results from testing the 1,7-
DAAC SMNPIs in a cell-based infection assay, using Vero76
(African green monkey kidney cells), indicated that the majority
of the derivatives are toxic when administered at 20 μM
concentration. However, 11, 14, 16, and 17 were exceptions.
These SMNPIs provided 97%, 100%, 96%, and 53% EBOV
inhibition, respectively (Table 4). Following, dose-response
studies conducted for 11, 14, and 16 indicated that these
SMNPIs possess IC50 values in the 5 μM range (Table 4), with
cell toxicities of <25% (Figure 2). Hence, these three 1,7-DAAC
derivatives are among the most potent EBOV inhibitors dis-
covered to date.
’CONCLUSION
The identiﬁcation of a 1,7-DAAC-based SMNPI as an inhi-
bitor of the BoNT/A LC resulted in the syntheses of a variety of
derivatives;all provided inhibition of the enzyme. Furthermore,
the 3-D superimposition of originally identiﬁed 1,7-DAAC-based
SMNPI 1 and the 4,7-ACQ components of classical antimalarial
agents indicated good structural and chemical complementarity.
This prompted investigations to determine if the 1,7-DAAC-
based derivatives described in this study might also inhibit
P. falciparum (malaria). Additionally, a previous study indicated
that 9 inhibits the Ebola ﬁlovirus; therefore all 1,7-DAAC
derivatives were also examined against this pathogen. Hence,
the results presented herein provide SAR for the 1,7-DAAC
chemotype when examined against three diﬀerent pathogenic
targets: a bacterial toxin (the BoNT/A LC), a protozoan
(P. falciparum malaria), and a ﬁlovirus (EBOV).
Results from these studies indicate that the presented 1,7-
DAAC-based SMNPIs inhibit the three unrelated pathogens by
employing three diﬀerent mechanisms of action, thus demon-
strating the unique antipathogenic potential of this chemotype.
Speciﬁcally: (1) BoNT/A LC metalloprotease inhibition is
achieved via interaction with the enzyme’s substrate binding
cleft, (2) antimalarial eﬃcacy appears to result from the suppres-
sion of β-hematin formation (see Tables 2), and 3) anti-EBOV
eﬃcacy most likely results from the modulation of a host cellular
pathway (for example, a pathway facilitating viral assembly and
budding).27a,51
Interestingly, SAR for the inhibition of the three targets does
not indicate a general correlation between 1,7-DAAC derivative
side chain substitutions and related inhibitory potencies across
pathogens. For example, primary amino substituents on the side-
chains of the 1,7-DAAC core result in increased BoNT/A LC
inhibitory potency while incorporating the side chain basic
Table 3. Toxicity and Metabolic Stability of 1,7-DAAC Derivatives 11, 16, and 17a
P.f. in vitro activity
(IC50; IC90) nM
selectivity index
(IC50; IC90)
b
compd
toxicity against
RAW 264.7
(IC50; IC90) nM D6 W2 C235 D6 W2 C235
metabolic stability t1/2
(HLM; MLM, min)
11 9348; 10717 6.01; 9.01 3.48; 10.12 3.32; 3.79 1555.41; 1189.46 2686.21; 1058.99 281.66; 2827.70 >60; >60; no toxicity in vivo
16 7481; 11029 5.23; 8.47 2.00; 6.38 8.05; 17.36 1430.40; 1302.12 3740.50; 1728.68 929.32; 635.31 40; >60
17 10174; 29916 5.93; 12.60 6.12; 11.50 9.84; 16.48 1715.68; 2374.36 1662.42; 2601.48 1033.94; 1815.35 >60; >60
aThe toxicities of all 1,7-DAAC derivatives are provided in the Supporting Information, Table S1. b Selectivity index: SI = ICtox/ICP.f. activity.
Table 4. In Vitro Inhibition of EBOV by Select Derivatives
11, 14, 16, and 17
SMNPI inhibition at 20 μM (%) IC50 (μM) toxicity at 20 μM (%)
11 97 5-10 <20
14 100 ∼5 <20
16 96 2.5-5 <20
17 53
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nitrogen in piperidine and morpholine rings favors antimalarial
activity, especially against drug resistant strains, without observed
toxic eﬀects. Finally, it is important to note that the inhibitory
eﬃcacies provided by the 1,7-DAAC derivatives described herein
indicate that they are among the most potent SMNPIs reported
to date for all three of the examined pathogenic targets.
’EXPERIMENTAL SECTION
General. Melting points were determined on a Boetius PMHK
apparatus and were not corrected. IR spectra were recorded on a Perkin-
Elmer spectrophotometer FTIR 1725X. 1H and 13C NMR spectra were
recorded on a Varian Gemini-200 spectrometer (at 200 and 50 MHz,
respectively) and a Bruker Ultrashield Advance III spectrometer (at 500
and 125 MHz, respectively) in the indicated solvent (vide infra) using
TMS as internal standard. Chemical shifts are expressed in ppm (δ)
values and coupling constants (J) in Hz. ESI-MS (HRMS) spectra of
synthesized compounds were acquired on a Agilent Technologies 1200
series instrument equipped with Zorbax Eclipse Plus C18 (100 mm 
2.1 mm i.d. 1.8 μm) column and DAD detector (190-450 nm) in
combination with a 6210 time-of-flight LC/MS instrument in the
positive ion mode. The samples were dissolved in pure H2O (HPLC
grade). The selected values were as follows: capillary voltage 4 kV, gas
temperature 350 C, drying gas 12 L min-1, nebulizer pressure 45 psig,
fragmentator voltage 70 V. Lobar LichroPrep Si 60 (40-63 μm) or
LichroPrep RP-18 columns coupled to a Waters RI 401 detector
were used for preparative column chromatography. For metabolism
experiments, incubations were separated on a Waters XTerra 3.5 μm,
2.0 mm  50 mm C18 column using a formic acid/acetonitrile mobile
phase. Analyses were preformed using a Surveyor separations module
coupled to a ThermoFinnigan TSQ AM triple quadrupole mass spectro-
meter. Mass spectral analyses were done using electrospray ionization in
positive ion mode.
Compounds were analyzed for purity (HPLC) using a Waters 1525
HPLC dual pump system equipped with an Alltech, Select degasser
system, and dual λ 2487 UV-vis detector. Octadecylsilica was used as
the stationary phase (Symmetry C18 analytical column, 4.6 mm 
150 mm, 5 μm, series no. 021336278136 37). Eluent was made from the
following solvents: 0.2% formic acid in water (A) and methanol (B). For
data processing, Empower software was used. All compounds were
>95% pure (for details, see Supporting Information, S5-S44).
Diethyl (2(Z or E),20(Z or E))-3,30-[Naphthalene-1,5-diyldi-
(imino)]bisbut-2-enoate (3). A suspension of 1,5-diaminonaphtha-
lene (5 g, 31.61 mmol (commercial, Sigma-Aldrich)), ethyl acetoacetate
(40mL, (commercial, Sigma-Aldrich)), and p-TsOH (2.38 g, 15.50mmol)
in anhyd EtOH (250mL) was heated to reflux in a two-neck round-bottom
flask equipped with a Dean-Stark trap filled with molecular sieves (4 Å).
After heating for 4 h (oil bath temp. 120 C) with stirring, the mixture was
cooled to rt and evaporated to dryness. The crude product was triturated
with EtOH, and precipitate was collected in a B€uchner funnel and dried
under reduced pressure to afford 11.39 g (94%) of 3 as a light-brown
powder. IR (ATR): 3442, 3253, 2977, 2923, 1652, 1606, 1506, 1440, 1267,
1158, 787 cm -1.
3,9-Dimethyl-4,10-dihydroquino[8,7-h]quinoline-1,7-dione
(4). A mixture of 3 (2 g, 5.23 mmol) and Eaton’s reagent (5.5 mL,
29.06mmol (commercial, Sigma-Aldrich)) was stirred at 90 C for 5 h. The
reaction mixture was cooled to 5 C (ice bath) and carefully poured onto
saturated ice-cold Na2CO3 solution (31 g Na2CO3/100 mL H2O). The
solid was filtered, and filtrate was washed with water (3 50mL), EtOH
(10 mL), and dried under reduced pressure at 50 C to afford 1.43 g
(94%) of dione 4 as a light-brown powder; mp > 280 C. IR (ATR):
3227, 3169, 3059, 2978, 1630, 1601, 1546, 1520, 1492, 1434, 1354, 1211,
1153, 1029, 843 cm-1. 1HNMR (200MHz, TFA-d): 9.15 (d, J= 9.6Hz,
2H), 8.87 (d, J = 9.6 Hz, 2H), 7.58 (s, 2H), 3.15 (s, 6H) ppm. 13C NMR
(50 MHz, TFA-d): 172.18, 139.66, 130.28, 127.79, 125.15, 123.15,
121.93, 111.70, 22.27 ppm.
1,7-Dichloro-3,9-dimethylquino[8,7-h]quinoline (5). A sus-
pension of 4 (1.37 g, 4.73 mmol) in POCl3 (28.38 mL) was heated at
90 C for 6 h, with continued heating at 120 C for 14 h. Upon cooling to rt,
the mixture was slowly poured onto an ice/water mixture, and concd aq
NH3 was added until pH 9 as achieved. Formed precipitate was filtered and
washed well with H2O and EtOH. Obtained dichloride 5 was dried under
reduced pressure at 60 C. Yield: 1.4442 g (93%);mp > 280 C. IR (ATR):
2922, 1582, 1481, 1432, 1359, 1083, 1027, 877, 849, 829, 749 cm -1. 1H
NMR(200MHz,TFA-d): 9.30 (d, J=9.6Hz, 2H), 8.78 (d, J=9.6Hz, 2H),
8.18 (s, 2H), 3.10 (s, 6H) ppm. 13C NMR (50 MHz, TFA-d): 162.18,
158.98, 138.44, 129.65, 129.52, 128.30, 127.52, 126.19, 22.45 ppm.
General Procedure for the Synthesis of 1,7-Bis(alkyl-
amino)diazachrysene Tetrahydrochloride (1, and 6-17). A
suspension of dichloride 5 (200mg, 0.61mmol) in corresponding amine
(10 mL) was stirred at reflux under argon for 60 h. Themixture was then
poured onto ice-cold water (40 mL), and the solid was filtered, washed
well with MeOH (5 mL), and dried at 45 C under reduced pressure.
Obtained crude base was then suspended in MeOH (12 mL), followed
by addition of EtOH/HCl solution (24 mL, 8.6M), and the reaction
mixture was vigorously stirred for 36 h at rt. The solvent was then
removed under reduced pressure, and the remaining solid was sus-
pended in 96% EtOH (15 mL), filtered, and washed well with 96%
Figure 2. Dose-response results for 1,7-DAAC derivative 11-, 14-, and 16-mediated Ebola ﬁlovirus inhibition in infected Vero76 cells (48 h incubation
period).
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EtOH (5 mL) and Et2O (5 mL). Upon drying at 45 C under reduced
pressure, desired product was obtained.
N,N0-Bis(4-aminobutyl)-3,9-dimethylquino[8,7-h]quinoline-1,7-
diamine Tetrahydrochloride (6). Dichloride 5 (200 mg, 0.61 mmol)
was transformed into 6 using the general procedure provided above,
with corresponding amine (butane-1,4-diamine). Compound 6: yield
270.7 mg (68%); mp > 280 C. IR (KBr): 3455, 3208, 3046, 1636, 1609,
1566, 1504, 1442, 1363, 1343, 1290, 1152, 1094, 1041, 924, 830, 744 cm-1.
1H NMR (500MHz, D2O): 8.53 (d, J = 9.5 Hz, 2H), 8.23 (d, J = 9.0 Hz,
2H), 7.04 (s, 2H), 3.90-3.80 (m, 4H), 3.30-3.20 (m, 4H), 2.97 (s,
6H), 2.10-2.00 (m, 4H) ppm. 13C NMR (125 MHz, D2O): 157.75,
157.32, 137.51, 126.61, 122.87, 122.30, 117.13, 103.85, 45.88, 42.02,
27.47, 27.24, 23.01 ppm. ESI-HRMS (m/z): [M þ 2H]2þ 216.14891
(error -2.83 ppm), [M þ H]þ 431.29109 (error -1.58 ppm).
N,N0-Bis(3-aminopropyl)-3,9-dimethylquino[8,7-h]quinoline-1,7-
diamine Tetrahydrochloride (7). Dichloride 5 (200 mg, 0.61 mmol)
was transformed into 7 using the general procedure provided above,
with corresponding amine (propane-1,3-diamine). Compound 7: yield
194 mg (58%); mp > 280 C. IR (ATR): 3378, 3178, 3021, 1636, 1608,
1559, 1505, 1438, 1360, 1291, 1146, 1091, 1034, 985, 827, 742 cm-1. 1H
NMR (200 MHz, D2O): 8.28 (d, J = 9.6 Hz, 2H), 8.07 (d, J = 9.6 Hz,
2H), 7.05 (s, 2H), 4.00-3.80 (m, 4H), 3.45-3.30 (m, 4H), 2.92 (s,
6H), 2.50-2.30 (m, 4H) ppm. 13C NMR (50 MHz, D2O): 157.76,
157.52, 137.33, 126.33, 122.87, 122.18, 116.97, 104.04, 43.59, 40.04,
28.50, 23.18 ppm. ESI-HRMS (m/z): [M þ 2H]2þ 202.13390 (error
0.12 ppm), [M þ H]þ 403.26024 (error -0.58 ppm).
N,N0-Bis(2-aminoethyl)-3,9-dimethylquino[8,7-h]quinoline-1,7-
diamine Tetrahydrochloride (8). Dichloride 5 (200 mg, 0.61 mmol)
was transformed into 8 using the general procedure provided above,
with corresponding amine (ethane-1,2-diamine). Compound 8: yield
197 mg (62%); mp > 280 C. IR (ATR): 3425, 3187, 3043, 1634, 1615,
1565, 1508, 1440, 1380, 1345, 1273, 1159, 1094, 1030, 950, 834, 745 cm-1.
1H NMR (200MHz, D2O): 8.67 (d, J = 9.4 Hz, 2H), 8.32 (d, J = 9.4 Hz,
2H), 7.18 (s, 2H), 4.25-4.10 (m, 4H), 3.70-3.50 (m, 4H), 3.00 (s, 6H)
ppm. 13C NMR (50 MHz, D2O): 158.31, 158.21, 137.80, 126.97,
123.33, 122.82, 117.79, 104.37, 43.28, 40.19, 23.07 ppm. ESI-HRMS
(m/z): [M þ 2H]2þ 188.11949 (error 6.73 ppm), [M þ H]þ
375.22869 (error -1.29 ppm).
N,N0-Bis[3-(dimethylamino)propyl]-3,9-dimethylquino[8,7-h]quin-
oline-1,7-diamine tetrahydrochloride (9). Dichloride 5 (160 mg, 0.49
mmol) was transformed into 9 using the general procedure provided
above, with corresponding amine (N,N-dimethylpropane-1,3-diamine).
Compound 9: yield 222mg (75%);mp > 280 C. IR (ATR): 3354, 3210,
2964, 2681, 2477, 1633, 1608, 1565, 1469, 1439, 1356, 1041, 830, 745
cm-1. 1H NMR (500 MHz, CD3OD): 8.99 (d, J = 9.5 Hz, 2H), 8.66 (d,
J = 9.6 Hz, 2H), 7.16 (s, 2H), 3.83-3.79 (m, 4H), 3.44-3.40 (m, 4H),
2.98 (s, 12H), 2.94 (s, 6H) ppm. 13C NMR (125 MHz, CD3OD):
157.03, 156.76, 137.09, 126.26, 122.57, 121.64, 116.73, 103.00, 56.57,
43.77, 42.02, 24.75, 21.12 ppm. ESI-HRMS (m/z): [M þ 2H]2þ
230.16557 (error 1.72 ppm), [M þ H]þ 459.32310 (error 0.07 ppm).
N,N0-Bis[2-(dimethylamino)ethyl]-3,9-dimethylquino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (10). Dichloride 5 (300 mg, 0.92
mmol) was transformed into 10 using the general procedure provided
above, with corresponding amine (N,N-dimethylethane-1,2-diamine).
Compound 10: yield 366 mg (69%); mp > 280 C. IR (ATR): 3430,
3361, 3180, 3068, 3029, 2974, 2699, 1634, 1609, 1554, 1445, 1344, 988,
828, 746 cm-1. 1H NMR (200 MHz, D2O): 8.69 (d, J = 9.6 Hz, 2H),
8.39 (d, J = 9.6 Hz, 2H), 7.24 (s, 2H), 4.34-4.20 (m, 4H), 3.89-3.78
(m, 4H), 3.22 (s, 12H), 3.02 (s, 6H) ppm. 13C NMR (50 MHz, D2O):
158.40, 138.50, 127.77, 123.58, 123.22, 118.57, 104.57, 57.56, 57.14,
46.01, 41.02, 23.00, 21.85, 17.74 ppm. ESI-HRMS (m/z): [Mþ 2H]2þ
216.14969 (error 0.78 ppm), [M þ H]þ 431.29161 (error 0.37 ppm).
N,N0-Bis[3-(diethylamino)propyl]-3,9-dimethylquino[8,7-h]qui-
noline-1,7-diamine Tetrahydrochloride (1). Dichloride 5 (160 mg,
0.49 mmol) was transformed into 1 using the general procedure
provided above, with corresponding amine (N,N-diethylpropane-1,3-
diamine). Compound 1: yield 210 mg (65%); mp > 280 C. IR (ATR):
3164, 2949, 2575, 2478, 1632, 1610, 1560, 1468, 1439, 1347, 1030, 821,
750 cm-1. 1HNMR (500MHz, CD3OD): 9.07 (d, J = 9.5 Hz, 2H), 8.74
(d, J = 9.5 Hz, 2H), 7.20 (s, 2H), 3.83-3.80 (m, 4H), 3.40-3.38 (m,
4H), 2.96 (s, 12H), 2.35-2.29 (m, 4H), 1.38 (t, J = 7.2 Hz, 12H) ppm.
13CNMR (125MHz, CD3OD): 157.20, 156.75, 137.19, 126.41, 122.66,
121.72, 116.87, 103.02, 50.98, 48.71, 24.24, 21.03, 9.36 ppm. ESI-HRMS
(m/z): [M þ 2H]2þ 258.19756 (error 2.08 ppm), [M þ H]þ
515.38770 (error 0.36 ppm).
N,N0-Bis[2-(diethylamino)ethyl]-3,9-dimethylquino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (11). Dichloride 5 (200 mg, 0.61
mmol) was transformed into 11 using the general procedure provided
above, with corresponding amine (N,N-diethylethane-1,2-diamine).
Compound 11: yield 212 mg (55%); mp > 280 C. IR (ATR): 3384,
3188, 3066, 2663, 1635, 1610, 1556, 1441, 1348, 1071, 830, 744 cm-1.
1H NMR (500 MHz, CD3OD): 9.14 (d, J = 9.0 Hz, 2H), 8.85 (d, J = 9.0
Hz, 2H), 7.30 (s, 2H), 4.18-4.14 (m, 4H), 3.68-3.63 (m, 4H),
3.46-3.38 (m, 8H), 2.97 (s, 6H), 1.44-1.40 (m, 12H) ppm. 13C
NMR (125 MHz, CD3OD): 157.37, 157.22, 137.49, 126.68, 123.01,
121.88, 117.29, 103.41, 51.11, 39.68, 21.05, 9.16 ppm. ESI-HRMS (m/
z): [M þ 2H]2þ 244.18208 (error 5.13 ppm), [M þ H]þ 487.35548
(error 2.28 ppm).
3,9-Dimethyl-N,N0-bis(3-pyrrolidin-1-ylpropyl)quino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (12). Dichloride 5 (200 mg, 0.61
mmol) was transformed into 12 using the general procedure provided
above, with corresponding amine ((3-pyrrolidin-1-ylpropyl)amine).
Compound 12: yield 255 mg (76%); mp > 280 C. IR (ATR): 3410,
3079, 2960, 2762, 1639, 1612, 1565, 1509, 1441, 1362, 1168, 1086, 1042,
831, 744 cm -1. 1H NMR (200 MHz, D2O): 8.51 (d, J = 9.6 Hz, 2H),
8.23 (d, J = 9.6 Hz, 2H), 7.14 (s, 2H), 4.00-3.80 (m, 8H), 3.70-3.50
(m, 4H), 3.40-3.20 (m, 4H), 2.99 (s, 6H), 2.60-2.10 (m, 12H) ppm.
13C NMR (50 MHz, D2O): 157.80, 137.46, 126.57, 123.05, 122.45,
117.26, 104.08, 57.17, 55.10, 43.41, 27.22, 25.51, 23.03 ppm. 1H NMR
(500MHz, D2O): 8.55 (d, J = 9.5 Hz, 2H), 8.26 (d, J = 9.5 Hz, 2H), 7.13
(s, 2H), 3.95-3.90 (m, 8H), 3.65-3.55 (m, 4H), 3.35-3.30 (m, 4H),
3.01 (s, 6H), 2.50-2.40 (m, 4H), 2.40-2.30 (m, 4H), 2.25-2.15 (m,
4H) ppm. 13C NMR (125 MHz, D2O): 154.68, 154.57, 134.39, 123.52,
119.83, 119.32, 114.16, 100.86, 54.05, 51.98, 40.24, 24.10, 22.39, 19.92
ppm. ESI-HRMS (m/z): [M þ 2H]2þ 256.18065 (error -0.66 ppm),
[M þ H]þ 511.35409 (error -0.55 ppm).
3,9-Dimethyl-N,N0-bis(2-pyrrolidin-1-ylethyl)quino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (13). Dichloride 5 (250 mg, 0.76
mmol) was transformed into 13 using the general procedure provided
above, with corresponding amine ((2-pyrrolidin-1-ylethyl)amine).
Compound 13: yield 302 mg (68%); mp > 280 C. IR (ATR): 3418,
3225, 3066, 2709, 1635, 1611, 1556, 1510, 1441, 1346, 1031, 828,
745 cm -1. 1HNMR (200MHz, D2O): 8.87 (d, J = 9.6 Hz, 2H), 8.48 (d,
J = 9.6 Hz, 2H), 7.20 (s, 2H), 4.40-4.20 (m, 4H), 4.05-3.70 (m, 8H),
3.50-3.10 (m, 4H), 3.02 (s, 6H), 2.40-2.00 (m, 8H) ppm. 13C NMR
(50MHz, D2O): 158.36, 138.20, 127.41, 123.53, 123.04, 118.19, 104.50,
57.54, 54.88, 42.23, 25.55, 23.03 ppm. ESI-HRMS (m/z): [Mþ 2H]2þ
242.16524 (error 0.27 ppm), [MþH]þ 483.32241 (error-1.36 ppm).
3,9-Dimethyl-N,N0-bis(3-piperidin-1-ylpropyl)quino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (14). Dichloride 5 (200 mg, 0.61
mmol) was transformed into 14 using the general procedure provided
above, with corresponding amine ((3-piperidin-1-ylpropyl)amine).
Compound 14: yield 330 mg (79%); mp > 280 C. IR (ATR): 3361,
3182, 2944, 2536, 1636, 1606, 1562, 1438, 1354, 835, 745 cm-1. 1H
NMR (500MHz, CD3OD): 9.11 (d, J = 8.5 Hz, 2H), 8.77 (d, J = 8.5 Hz,
2H), 7.18 (s, 2H), 3.83-3.79 (m, 4H), 3.62 (bd, J = 12 Hz, 4H),
3.37-3.30 (m, 4H), 3.07-2.95 (m, 4H), 2.95 (s, 6H), 2.39-2.32
(m, 4H), 2.00-1.84 (m, 10H), 1.59-1.51 (m, 2H) ppm. 13C NMR
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(125 MHz, CD3OD): 157.29, 156.73, 137.27, 126.55, 122.71, 121.69,
116.96, 55.75, 54.64, 42.12, 24.43, 24.12, 22.86, 20.97 ppm. ESI-HRMS
(m/z): [M þ 2H]2þ 270.19601 (error 1.73 ppm), [M þ H]þ
539.38481 (error 1.61 ppm).
3,9-Dimethyl-N,N0-bis(2-piperidin-1-ylethyl)quino[8,7-h]quinoline-
1,7-diamine Tetrahydrochloride (15). Dichloride 5 (200 mg, 0.61
mmol) was transformed into 15 using the general procedure provided
above, with corresponding amine ((2-piperidin-1-ylethyl)amine). Com-
pound 15: yield 224 mg (56%); mp > 280 C. IR (ATR): 3345, 3224,
2943, 2644, 1634, 1608, 1564, 1438, 1360, 831, 744 cm-1. 1H NMR
(500MHz, D2O): 8.86 (d, J = 9.5 Hz, 2H), 8.48 (d, J = 9.5 Hz, 2H), 7.19
(s, 2H), 4.29-4.24 (m, 4H), 3.83 (bd, J = 12 Hz, 4H), 3.74-3.70 (m,
4H), 3.27-3.21 (m, 4H), 3.02 (s, 6H), 2.15-2.10 (m, 4H), 2.01-1.92
(m, 6H), 1.59-1.52 (m, 2H) ppm. 13CNMR (125MHz, D2O): 158.28,
158.21, 138.14, 127.37, 123.45, 122.95, 118.13, 104.39, 56.63, 40.54,
25.57, 23.81, 23.03 ppm. ESI-HRMS (m/z): [M þ 2H]2þ 256.18169
(error 3.38 ppm), [M þ H]þ 511.35584 (error 2.87 ppm).
3,9-Dimethyl-N,N0-bis(3-morpholin-4-ylpropyl)quino[8,7-h]quinoline-1,
7-diamine Tetrahydrochloride (16). Dichloride 5 (200 mg, 0.61 mmol)
was transformed into 16 using the general procedure provided above,
with corresponding amine ((3-morpholin-4-ylpropyl)amine). Com-
pound 16: yield 211mg (67%);mp> 280 C. IR (ATR): 3344, 3220, 3074,
2942, 2684, 2613, 2471, 1636, 1609, 1564, 1508, 1439, 1356, 1306, 1263,
1217, 1135, 1105, 1045, 963, 908, 862, 833, 744 cm-1. 1HNMR (200MHz,
D2O): 8.46 (d, J = 9 Hz, 2H), 8.21 (d, J = 9 Hz, 2H), 7.15 (s, 2H), 4.40-
3.40 (m, 24H), 2.98 (s, 6H), 2.60-2.30 (m, 4H) ppm. 13C NMR
(50 MHz, D2O): 157.78, 137.38, 126.48, 123.07, 122.42, 117.25, 104.17,
66.72, 57.41, 54.79, 43.37, 25.07, 23.07 ppm. ESI-HRMS (m/z): [M þ
2H]2þ 272.17515 (error -2.18 ppm), [M þ H]þ 543.34189 (error -
4.25 ppm).
3,9-Dimethyl-N,N0-bis(2-morpholin-4-ylethyl)quino[8,7-h]quino-
line-1,7-diamine Tetrahydrochloride (17). Dichloride 5 (270 mg, 0.82
mmol) was transformed into 17 using the general procedure provided
above, with corresponding amine ((2-morpholin-4-ylethyl)amine).
Compound 17: yield 417 mg (88%); mp > 280 C. IR (ATR): 3482,
3411, 3183, 3072, 2873, 2567, 2442, 1637, 1613, 1559, 1511, 1442, 1347,
1302, 1267, 1232, 1175, 1133, 1102, 1043, 906, 826, 744 cm -1. 1H
NMR (200 MHz, D2O): 8.91 (d, J = 9.6 Hz, 2H), 8.51 (d, J = 9.6 Hz,
2H), 7.20 (s, 2H), 4.40-4.10 (m, 12H), 3.90-3.50 (m, 12H), 3.03 (s,
6H) ppm. 13C NMR (50 MHz, D2O): 157.41, 137.40, 126.60, 122.54,
122.09, 117.32, 103.50, 65.63, 56.16, 54.09, 39.21, 22.12 ppm. ESI-
HRMS (m/z): [M þ 2H]2þ 258.16032 (error 0.91 ppm), [M þ H]þ
515.31241 (error -0.95 ppm).
Molecular Modeling (for Figure 1 SMNPI Superimposi-
tions). Insight II (v2005) (Accelrys, San Diego, USA) was used to
perform all molecular modeling. The structures of 1, 2, and CQ were
generated using the Builder module. Following, 1, 2, and CQ were each
energy minimized employing the Discover module (ccf91 forcefield,
distance dependent dielectic = 1). For each SMNPI, steepest descent
minimization was performed for 500 iterations, followed by conjugate
gradient minimization until the norm of the derivative was 0.001 kcal/Å.
SMNPIs were manually superimposed to achieve optimal steric and
atomic superimpositions (i.e., via translational, rotational, and bond
torsion adjustments).
In Vitro BoNT/A LC Metalloprotease Activity. Determina-
tion of BoNT/A LC percent inhibition by SMNPIs was performed as
previously described,31-33,36b-36d,36f,37 The assay uses an N-terminal
acetylated, C-terminal aminated, synthetic peptide with the same
sequence as residues 187-203 of SNAP-25. Because substrate hydro-
lysis is determined by HPLC separation of the products from the
substrate, and is followed by measuring peak areas, intrinsic compound
fluorescence quenching does not interfere with inhibition measure-
ments. Assay mixtures contained 40 mM HEPES-0.05% Tween (pH
7.3), recombinant BoNT/A LC, peptide substrate, 0.5 mg/mL bovine
serum albumin (BSA), and various SMNPI concentrations. The assay
was run at 37 C, quenched by the addition of TFA, and analyzed using
reverse-phase HPLC. Excess ZnCl2 (50 μM) was added to the assay to
ensure that the SMNPIs were not Zn(II) chelators. Measurements of
percent inhibition were performed in duplicate. The calculated Ki values
were determined based on the slopes of Dixon plots where Ki =
Km/(slope  Vmax S). S = the substrate conc. The reported Ki values
are the averages of three separate experiments incorporating nine
concentrations of SMNPI.
In Vitro Antimalarial Activity. The in vitro antimalarial drug
susceptibility screen is a modification of the procedures first published
by Desjardins et al.;45 the modifications were developed by Milhous
et al.46 Modification details are provided in ref 38. All SMNPIs were
screened in vitro against P. falciparum strains: CQ and MFQ susceptible
strain D6 (a clone of the Sierra I/UNC isolate), CQ resistant but MFQ
susceptible strainW2(a clone of the Indochina I isolate), andCQandMFQ
resistant strain TM91C235 (C235, a clone of a South-East Asian isolate).
In Vivo Antimalarial Efficacy Studies. The two mouse (Mus
musculus, ICR stock) antimalarial efficacy screens for blood and exoer-
ythrocytic stages of infection were conducted at the United States Army
Medical Component, Armed Forces Research Institute of Medical
Sciences (USAMC-AFRIMS) in Bangkok, Thailand. Study protocols
were approved by the USAMC-AFRIMS Institutional Animal Care and
Use Committee. Animals were cared for in accordance with the “Guide
for the Care and Use of Laboratory Animals” published by the National
Research Council, 1996. The USAMC-AFRIMS’ animal care and use
program has been accredited by the Association for the Assessment and
Accreditation of Animal Care International (AAALAC International).
Brieﬂy, for the blood-stagemodel, groups of ﬁvemice were inoculated
intraperitoneally on day 0 with 1.0 106 P. berghei (P Line) (parasitized
erythrocytes were obtained from infected donor mice). SMNPIs were
suspended in 0.5% hydroxyethylcellulose:0.1% Tween 80 (HECT) and
administered orally once daily for three consecutive days (beginning on
day 3 postinfection). Untreated vehicle control mice succumbed to
infection on days 6-8 (postinfection). Blood smear samples were
obtained from each animal to determine parasitemia by snipping the
tip of the tail for thick and thin blood ﬁlms on two microscope glass
slides on study days 0, 3, 6, 10, 13, 17, 20, 24, 27, and 31 (postinfection).
Blood smear samples on glass slides were ﬁxed in methanol and stained
with Giemsa stain. Thick ﬁlms, to determine the presence or absence of
parasite, under oil-immersion lightmicroscopy objective, were examined
ﬁrst. If positive, the thin ﬁlms were then examined for the detection of
malaria infected erythrocytes (percent parasitemia) by counting a total
of 500 erythrocytes (at >1%), 1000 erythrocytes (at <1%), 10000
erythrocytes (at <0.1%), and 50000 erythrocytes (<0.01%). Mice were
observed twice daily for clinical signs and individual weights were
obtained on days 0, 3-7, 10, 13, 17, 20, 24, 27, and 31. Mice were
humanely euthanized if showing moribund condition (i.e., unable to
move), and two blood smears were obtained prior to euthanasia. Cure
was deﬁned as survival until day 31 post-SMNPI treatment, with no
evidence of blood parasite and without evidence of malaria infection
upon necropsy (i.e., common gross necropsy lesions).
For the exoerythrocytic model, infected sporozoites were harvested
from laboratory-raised Anopheles dirus mosquitoes that were fed on
donor mice infected with P. berghei (ANKA strain) at >8% parasitemia,
with the presence of gametocytes. After incubating the mosquitoes at
19 C for a minimum of 18 days, the mosquito salivary glands were
dissected and suspended in phosphate buﬀered saline with 5% BSA. The
fresh sporozoite suspension was counted for 100 microscopic ﬁelds
using a hemacytometer under phase-contrast microscopy to determine
the number of sporozoites per mL. All mice were randomized into
groups (one vehicle control group and up to 10 experimental groups) as
required. SMNPIs were suspended in 0.5% hydroxyethylcellulose:0.1%
Tween 80 (HECT). On day -1, day 0 (within 1 to 3 h prior to
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inoculation), and day 1, each mouse in each test group received SMNPI
at the determined dose by plastic oral gavage tubes. Control animals
received the same amount of the vehicle without SMNPI. On day 0, all
mice were infected by a standard 0.1 mL dose of 1.0  105 P. berghei
(ANKA strain) sporozoites by intravenous (IV) inoculation. Animal
weights were obtained on study days-1, 0, 1, 6, 10, 15, 21, and 31. Blood
smear samples were obtained by snipping the tip of the tail for thick and
thin blood ﬁlms on two microscope glass slides from each animal on
study days 4, 5, 6, 7, 10, 15, 21, and 31 postinfection (to determine
parasitemia). Blood smear samples on glass slides were ﬁxed inmethanol
and stained with Giemsa stain. Thick ﬁlms for the presence or absence of
parasite, under oil-immersion light microscopy, were examined ﬁrst. If
positive, then thin ﬁlms were examined for the detection of malaria
infected erythrocytes (percent parasitemia) by counting a total of 500
erythrocytes (at >1%), 1000 erythrocytes (at <1%), 10000 erythrocytes
(at <0.1%), and 50000 erythrocytes (at <0.01%). On day 5 and after-
ward, any animal with parasitemia exceeding 5% was euthanized. Mice
were observed twice daily for clinical signs and mortality. Mortality and
clinical signs were recorded. During days 10 and 31, if any clinical sign
was observed, two blood smears were obtained. If parasitemia was
detected, blood smears were conducted 2-3 times weekly. Moribund
animals showing combined clinical signs within the early end point
criteria (i.e., unable to move or severe depression with reduced appetite,
extreme pallor, and ruﬄed hair) were euthanized by employing CO2.
Prior to euthanasia, two blood smears were obtained for parasitemia
determination. Mice surviving to day 31 were euthanized by CO2. All mice
underwent necroscopy. SMNPIs, at tested doses, were considered causal
prophylactics against malarial infection if the animals in that test group did
not develop parasitemia within 10 days postinfection, and blood smear
results remained negative throughout the 31 day experiment.
In Vitro Metabolism. Metabolic stability assay sample prepara-
tion was performed in a 96-well plate format using a TECAN Genesis
robotic sample processor following WRAIR SOP SP 01-09. All
incubations were carried out in 0.1 M sodium phosphate buffer (pH
7.4) in the presence of an NADPH-regenerating system (NADPþ
sodium salt, MgCl2 3 6H2O, and glucose-6-phosphate). SMNPIs
(10 μM), microsomes (1 mg/mL total protein), buffer, and NADPH-
regenerating system were warmed to 37 C, and the reaction was
initiated by the addition of glucose-6-phosphate dehydrogenase
(G6PD). Samples were quenched at 0, 10, 30, and 60 min using an
equal volume of cold acetonitrile. Samples were centrifuged to pellet the
proteins, and the supernatant was analyzed by LC-MS/MS using fast LC
gradient methods. Depletion of parent SMNPI signal was monitored
relative to signal at time 0. Chromatograms were analyzed using themass
spectrometry software Xcalibur QuanBrowser. To calculate SMNPI
half-lives, a first-order rate of decay was assumed. A plot of the natural log
(LN) of the compound concentration versus time was generated in
which the slope of that line was-k. Half-lives were calculated as 0.693/k.
Hepatic microsomal intrinsic clearance was calculated using the formula
CLint,in vitro = (rate/min)  (mL/0.5 g)  52.5 mg/g liver or CLint,in vitro =
k  (microsomal protein content per gram of liver)/(microsomal
protein concentration in incubation buffer).
In Vitro Toxicity: Assessment of SMNPI Toxicity in a RAW
264.7 (Rat Macrophage) Cell Line. Macrophage cell line RAW
264.7 was obtained from the American Type Culture Collection and was
cultured as previously described.52 All steps of the experimental proce-
dure were performed using a Biomek 2000 robot. Then 96-well plates
were seeded with 2.5  104 cells per well in 170 μL of culture medium
approximately 12 h before the start of the assay. The following morning,
cells were exposed to different SMNPI concentrations ranging from 0.29
to 48 μg/mL and were incubated at 37 C, 5% CO2, for 48 h. Cell
viability was assessed using the MTT (thiazolyl blue reduction) method
as previously described.52 Each assay plate included a background, a
target, and a DMSO control. All experiments were run in duplicate, and
50% inhibitory concentrations (IC50) were determined using GraphPad
Prism (sigmoidal dose-response, variable slope).
β-Hematin Inhibitory Activity Assay. The inhibition of β-
hematin formation by SMNPIs 12, 15, and 16 was carried out using a β-
hematin inhibitory activity (BHIA) assay. The full details of the assay
have been published,39 and the assay was performed exactly as described
in the indicated reference.
Antiviral Studies. The cell culture employed: Vero76 (African
greenmonkey kidney) cells (ATCCCRL-1587) were grown in Dulbecco’s
Minimal Essential Medium with low bicarbonate, 10% fetal bovine
serum, 1 mM sodium pyruvate, and 1% non essential amino acid.
Recombinant Zaire Ebola virus (EBOV) engineered to express the
enhanced GFP (EBOV-eGFP) gene was a kind gift from Dr. Stuart Nichol
(CDC, Atlanta). The generation and characterization of this virus has been
described elsewhere.47 The EBOV-eGFP virus was propagated in Vero76
cells and viral titer was determined using a standard plaque assay.48
The details of the Ebola-eGFP infection assay are described
elsewhere.49 Brieﬂy, Vero76 cells (4  104 cells/well) were seeded in
96-well BD high content imaging plates (BD Biosciences) and allowed
to incubate overnight. For primary screening of the SMNPIs, the cells
were pretreated with a single concentration (10 or 20 μM) for 2 h and
then infected in the presence of SMNPI with EBOV-eGFP at a multi-
plicity of infection (MOI) of 5. After incubation for 48 h at 37 C under
5% CO2, the cells were ﬁxed in 10% formalin for 3 days and then washed
three times with phosphate buﬀered saline (PBS). Cells infected with
Ebola-eGFP were stained with HCS Cellmask Deep Red cytoplasmic/
nuclear stain (Invitrogen, 5 μg/mL diluted in PBS) and nuclear Hoechst
dye 33342 (Invitrogen, 1 μg/mL diluted in PBS).
For dose-response studies, SMNPIs were diluted 2-fold and in-
cubated with the cells in the presence of Ebola-eGFP as described
elsewhere.49 For both of the viral infection assays, automated image
acquisition of the plates were performed using an Opera confocal reader
(model 3842-quadruple excitation high sensitivity (QEHS), Perkin-
Elmer, Waltham, MA 02451). The images were analyzed within the
Opera environment using standard Acapella scripts.
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